MARKET

OMER

OMER

Omeros
NASDAQ

Real-time Quotes | Nasdaq Last Sale

18.13
-0.25
-1.33%
Opening 11:21 04/19 EDT
OPEN
18.26
PREV CLOSE
18.37
HIGH
18.26
LOW
17.84
VOLUME
113.23K
TURNOVER
--
52 WEEK HIGH
25.46
52 WEEK LOW
9.25
MARKET CAP
1.12B
P/E (TTM)
-7.5195
1D
5D
1M
3M
1Y
5Y
Omeros Stock Is Estimated To Be Modestly Overvalued
GuruFocus News · 8h ago
Global Gastrointestinal Stromal Tumor (GIST) Drug Market Outlook, Industry Analysis and Prospect 2021-2026
Apr 15, 2021 (Heraldkeepers) -- The Gastrointestinal Stromal Tumor (GIST) Drug market report provides a detailed analysis of global market size, regional and...
Heraldkeepers · 4d ago
Global Epstein-Barr Virus (HHV-4) Infections Treatment Market Outlook, Industry Analysis and Prospect 2021-2026
Heraldkeepers · 4d ago
Global Atypical Hemolytic Uremic Syndrome Drug Market Outlook, Industry Analysis and Prospect 2021-2026
Apr 15, 2021 (Heraldkeepers) -- The Atypical Hemolytic Uremic Syndrome Drug market report provides a detailed analysis of global market size, regional and...
Heraldkeepers · 4d ago
Memory Impairment Treatment Market Size Analysis by Competitive Landscape 2021 Latest Research by Top Key Players, Global Share with SWOT Analysis, and Growth Analysis with Revenue till 2027
Apr 14, 2021 (The Expresswire) -- "Final Report will add the analysis of the impact of COVID-19 on this industry." Global “Memory Impairment Treatment...
The Express Wire · 5d ago
Omeros Corp (OMER) CHAIRMAN, CEO & PRESIDENT Gregory A Md Demopulos Sold $1.3 million of Shares
GuruFocus News · 04/08 16:57
Atypical Hemolytic Uremic Syndrome Drug Market Research Report by Type, by Product, by Application - Global Forecast to 2027 - Cumulative Impact of COVID-19
Apr 06, 2021 (Market Insight Reports) -- CANADA - QYResearchMedical recently added a research report, Atypical Hemolytic Uremic Syndrome Drug market – global...
Market Insight Reports · 04/06 19:32
COVID-19 Pandemic Effect and Impact Analysis on Epstein-Barr Virus (HHV-4) Infections Treatment Market by 2027
Apr 06, 2021 (Market Insight Reports) -- CANADA - QYResearchMedical recently added a research report, Epstein-Barr Virus (HHV-4) Infections Treatment market...
Market Insight Reports · 04/06 19:09
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of OMER. Analyze the recent business situations of Omeros through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 7 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average OMER stock price target is 27.33 with a high estimate of 34.00 and a low estimate of 18.00.
EPS
Institutional Holdings
Institutions: 185
Institutional Holdings: 36.16M
% Owned: 58.38%
Shares Outstanding: 61.93M
TypeInstitutionsShares
Increased
43
1.94M
New
16
635.49K
Decreased
42
2.35M
Sold Out
17
903.34K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-1.82%
Pharmaceuticals & Medical Research
-0.47%
Key Executives
Chairman/President/Chief Executive Officer/Director
Gregory Demopulos
Chief Accounting Officer/Vice President - Finance/Treasurer
Michael Jacobsen
Chief Scientific Officer/Vice President
George Gaitanaris
Vice President/General Counsel/Secretary
Peter Cancelmo
Vice President
Christopher Bral
Vice President
Daniel Kirby
Vice President
Alexander Gragerov
Vice President
Bruce Meiklejohn
Vice President
Catherine Melfi
Vice President
Tina Quinton
Vice President
J. Steven Whitaker
Vice President - Business Development
Timothy Duffy
Other
Nadia Dac
Lead Director/Independent Director
Thomas Cable
Director
Peter Demopulos
Independent Director
Ray Aspiri
Independent Director
Thomas Bumol
Independent Director
Arnold Hanish
Independent Director
Leroy Hood
Independent Director
Rajiv Shah
Independent Director
Kurt Zumwalt
No Data
  • All
  • Financials
  • Insiders
More
About OMER
Omeros Corporation is a commercial-stage biopharmaceutical company. The Company is engaged in discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, complement-mediated diseases and disorders of the central nervous system. The Company’s drug product OMIDRIA (phenylephrine and ketorolac intraocular solution) is used during cataract surgery or intraocular lens (IOL) replacement. The Company’s clinical-stage development programs are focused on complement-associated thrombotic microangiopathies, complement-mediated glomerulonephropathies, Huntington’s disease and cognitive impairment, and addictive and compulsive disorders. It also offers a diverse group of preclinical programs and platforms that are used to unlock new G protein-coupled receptor (GPCR) drug targets and to generate antibodies.

Webull offers kinds of Omeros Corporation stock information, including NASDAQ:OMER real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, OMER stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading OMER stock methods without spending real money on the virtual paper trading platform.